eCite Digital Repository

Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: A translational assay compared with conventional IHC

Citation

Yeong, J and Tan, T and Chow, Z and Cheng, Q and Lee, B and Seet, A and Lim, JX and Lim, JCT and Ong, CCH and Thike, AA and Saraf, S and Tan, BYC and Poh, YC and Yee, S and Liu, J and Lim, E and Iqbal, J and Dent, R and Tan, PH, Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: A translational assay compared with conventional IHC, Journal of Clinical Pathology, 73, (9) pp. 557-562. ISSN 0021-9746 (2020) [Refereed Article]


Preview
PDF
Not available
1Mb
  

DOI: doi:10.1136/jclinpath-2019-206252

Abstract

Background:Programmed death-ligand 1 (PD-L1) monoclonal antibody therapy has recently gained approval for treating metastatic triple-negative breast cancer (TNBC) -, in particular in the PD-L1+ patient subgroup of the recent IMpassion130 trial. The SP142 PD-L1 antibody clone was used as a predictive assay in this trial, but this clone was found to be an outlier in previous harmonisation studies in lung cancer.

Aims: To address the comparability of PD-L1 clones in TNBC, we evaluated the concordance between conventional immunohistochemistry (IHC) and multiplex immunohistochemistry/immunofluorescence (mIHC/IF) that allowed simultaneous quantification of three different PD-L1 antibodies (22C3, SP142 and SP263).

Methods: Our cohort comprised 25 TNBC cases, 12 non-small-cell lung carcinomas and 8 other cancers. EpCAM labelling was used to distinguish tumour cells from immune cells.

Results: Moderate-to-strong correlations in PD-L1 positivity were found between results obtained through mIHC/IF and IHC. Individual concordance rates in the study ranged from 67% to 100%, with Spearman's rank correlation coefficient values up to 0.88.

Conclusions: /IF represents a promising tool in the era of cancer immunotherapy, as it can simultaneously detect and quantify PD-L1 labelling with multiple antibody clones, and allow accurate evaluation of tumour and immune cells. Clinicians and pathologists require this information to predict patient response to anti-PD-1/PD-L1 therapy. The adoption of this assay may represent a significant advance in the management of therapeutically challenging cancers. Further analysis and assay harmonisation are essential for translation to a routine diagnostic setting.

Item Details

Item Type:Refereed Article
Keywords:breast pathology, immunohistochemistry, immunopathology
Research Division:Biomedical and Clinical Sciences
Research Group:Oncology and carcinogenesis
Research Field:Cancer therapy (excl. chemotherapy and radiation therapy)
Objective Division:Health
Objective Group:Clinical health
Objective Field:Treatment of human diseases and conditions
UTAS Author:Chow, Z (Mr Zi Long Chow)
ID Code:152337
Year Published:2020
Web of Science® Times Cited:29
Deposited By:Menzies Institute for Medical Research
Deposited On:2022-08-17
Last Modified:2022-08-17
Downloads:0

Repository Staff Only: item control page